A key deadline passed at the end of June. Public comments on the FDAs proposal to end large-scale compounding of semaglutide, tirzepatide, and liraglutide closed, moving a final decision one step closer.
At the end of June 2026, the public comment window closed on the FDAs proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the main pathway for large-scale compounding. The FDA will now weigh comments before a final decision; finalizing would sharply reduce compounded GLP-1 availability. Compounded versions are not FDA-approved.
A regulatory milestone for compounded weight-loss drugs passed quietly at the end of June.
With the comment window closed, attention turns to what the FDA does next.
The FDAs proposal, announced April 30 and formalized in a May 1 Federal Register notice, would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the list of bulk substances that outsourcing facilities may use to compound at scale. The agency found no clinical need for bulk compounding of these drugs now that FDA-approved versions are available and shortages have resolved. The public comment period closed at the end of June 2026, and the FDA will now consider submitted input before issuing a final determination.
Because the underlying shortages were already declared resolved, finalizing the exclusion would remove the main remaining route for large-scale compounding of these GLP-1s, leaving only narrow, patient-specific 503A compounding in limited cases. Analysts have suggested a final rule could follow later in 2026, though the timing is not guaranteed.
For consumers, the closed comment window signals that broadly available compounded GLP-1s are nearing the exit, pending a final rule. Compounded versions are not FDA-approved and have been linked to quality and dosing concerns; as approved products become more accessible, the case for compounded versions weakens further. The practical guidance sharpens: prioritize FDA-approved GLP-1s from licensed prescribers and pharmacies, and be cautious of sources still marketing compounded or unbranded versions.
Watch for the FDAs final determination and its timing, which would decide whether large-scale compounding of these GLP-1s ends. Pricing and access for approved products will shape the real-world impact. For individuals using compounded GLP-1s, the prudent step is to discuss FDA-approved alternatives with a prescriber rather than turning to unregulated or online sources as legitimate compounded supply contracts.